| abstract |
The present invention relates to PAR-1 antagonists in particular vorapaxar, atopaxar, and 3-(2-chloro-phenyl)-1]-4-(4-fluoro-benzyl)-piperazine-1-yl-propenone-3 (2-chlorophenyl) -1-[4-(4-fluorobenzyl)piperazin-1-yl]propenone or one of its pharmaceutically acceptable salts for use in the prevention and/or treatment of functional diseases of the pelvic and perineal region, particularly painful bladder syndrome. |